Skip to main content

Table 1 Characteristics of the included COS development studies in prostate cancer (n = 11)

From: A scoping review of core outcome sets and their ‘mapping’ onto real-world data using prostate cancer as a case study

First Author [ref] Year Study type Target population Methods for consensus Type of participants Number of participants Geographical origin
Auvinen A [21] 1996 COS for clinical trials or clinical research Men aged 56–67 eligible for screening Meeting Clinical experts; non-clinical research experts 26 Europe, Canada, United States
Chen RC [22] 2014 COS patient reported outcomes Adult patients (19+) with localized and advanced cancer Systematic literature review; meeting Clinical experts; non-clinical research experts; public representatives NA NA
Dawson NA [23] 1998 COS for clinical trials or clinical research Patients with hormone-refractory prostate cancer Survey Clinical experts 35 Europe, Canada, United States
Denis L [24] 1997 COS for clinical trials or clinical research Especially patients with localized cancer Meeting Clinical experts; others 6 Europe, United States
MacLennan S [25] 2017 COS for clinical trials or clinical research Patients aged 45–75 with localized prostate cancer undergoing surgery, active surveillance, ablative therapy, hormonal therapy Meeting; Delphi; focus group; systematic literature review Clinical experts; public representatives 105 patients + 47 clinical experts Europe, United States
Martin NE [26] 2015 COS for practice Men with newly diagnosed localized (stages T1-T4) cancer treated with curative intent or followed-up with active surveillance Delphi; teleconferences; survey Clinical experts; non-clinical research experts; public representatives NA NA
Middleton RG [27] 1995 COS for clinical trials or clinical research Patients with stage T2(B) prostate cancer undergoing radical prostectomy, radiation therapy, or surveillance Literature review NA NA United States
Morgans A [28] 2015 COS for practice Metastatic and recurrent patients ineligible for further curative therapy Delphi; literature review; teleconferences Clinical experts; non-clinical research experts; public representatives 25 Europe, Australia, Canada, United States
Schellhammer P [29] 1997 COS for clinical trials or clinical research Patients with localized cancer Literature review; conference Clinical experts; others NA Europe, Canada, United States
van den Bos W [30] 2014 COS for clinical trials or clinical research Patients with localized cancer and candidates for focal therapy Delphi; meeting; literature review Clinical experts 48 North America, Europe and Asia
van den Bos W [31] 2015 COS for clinical trials or clinical research Patients with localized recurrent disease after radiation therapy Delphi; meeting; literature review Clinical experts 55 NA
  1. COS Core outcome set, NA Not available